## **Special Issue**

# Delivery Systems of Peptides and Proteins: Challenges, Status Quo and Future Perspectives

## Message from the Guest Editors

Peptides and proteins have recently become more attractive therapeutic molecules than small molecular drugs due to their high selectivity and efficacy, but fewer side effects. With the advancement of biotechnology, more and more peptides and proteins would be developed as therapeutics. Hence, versatile drug delivery systems for pepetides and proteins would be an urgent need. In recent decades, a great number of scientists tried various technologies to alter the administration routes, prolong half-life or improve stability of peptides and proteins. Some technologies have been pushed toward clinical trials or even clinics, such as Eligen® for sameglutide and nasal delivery for glucagon. This special issue will collect manuscripts in delivery systems of peptides or proteins and figure out challenges, status quo and future development. Topics include formulation strategies, injectable delivery, oral delivery, nasal delivery, transdermal delivery, ocular delivery, long-acting delivery, targeted delivery of peptides and proteins and so on.

## **Guest Editors**

Prof. Dr. Jianping Qi School of Pharmacy, Fudan University, Shanghai 201203, China Dr. Haisheng He

School of Pharmacy, Fudan University, Shanghai 201203, China

## Deadline for manuscript submissions

closed (30 November 2022)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/97555

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





## **Pharmaceutica**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

